myelodysplastic syndromes

(The Myelodysplastic Syndromes Foundation) The Myelodysplastic Syndromes Foundation supports the positive opinion from the European Union's Committee for Medicinal Products for Human Use recommending approval of vidaza for specific types of MDS patients, including those with high-risk MDS, chronic myelomonocytic leukemia and acute myeloid leukemia.

(Weber Shandwick Worldwide) The Myelodysplastic Syndromes Foundation supports the decision by the US Food and Drug Administration to extend the label for vidaza to include data from the AZA-001 clinical trial.

Results from the trial found that azacitidine is the only agent which has been shown to extend survival in MDS patients.